Aethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatmen... (conducted by government and non-governme...)

Aethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatment Programs

Date:8/18/2010

conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.

As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:

Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.
Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.

The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.

In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glyco
'/>"/>

SOURCE Aethlon Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Aethlon Medical to Present at the 2009 RedChip Small-Cap Investor Conference on June 16, 2009
2. Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference
3. Aethlon Medical Releases Medical Device Data Against the H1N1 Swine Flu Virus
4. Aethlon Medical Discloses Live Webcast of Todays BIOCOM Presentation
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. Globus Medical Raises $110 Million in Series E Financing Round
9. Quark Pharmaceuticals Appoints New Chief Medical Officer
10. Boston University Biomedical Engineers Find Chink in Bacterias Armor
11. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial

Post Your Comments:

(Date:6/18/2013)... -- New-generation electronic designs are focused on rugged ... circuitry is increasing the number of functions it ... performs at. Connecting cables from the active elements ... as cameras or detectors, must be small, flexible ... custom cable designs for high-quality signal and EMI ...

(Date:6/18/2013)... And EMERYVILLE, Calif. , June ... final results today from a Phase 2/3 clinical ... demonstrating a statistically significant improvement in levodopa-induced dyskinesia ... week 8 versus placebo in the Unified Dyskinesia ... formulation of amantadine intended for once-nightly administration that ...

(Date:6/18/2013)... 18, 2013 Polymer Technology Systems, Inc. ... Health Group to integrate the CardioChek ® ... administered by health systems across the country. The ... and distributed through Hanson Medical Systems , ... cholesterol, LDL cholesterol, triglycerides, and glucose. ...

Breaking Medicine Technology:Omnetics Circular Connectors Offer Both Micro and Nano Interconnects for Highly Portable Electronic Systems, Meeting the Needs of Designers Looking for Size Reduction Options and Cable Flexibility 2 Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 2 Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 3 Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 4 Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 5 Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 6 Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 2 Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 3

[0] Omnetics Circular Connectors Offer Both Micro and Nano Interconnects for Highly Portable Electronic Systems, Meeting the Needs of Designers Looking for Size Reduction Options and Cable Flexibility [0] Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease [0] Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients

... WOODLANDS, Texas, Aug. 10, 2011 Lexicon Pharmaceuticals, ... company focused on discovering breakthrough treatments for human disease, ... trial of LX1031 in patients with non-constipating ... in the August 2011 edition of the journal ...

... Environmental testing and monitoring programs are essential ... understand industrial sterilization and contamination control procedures to bring ... In attempting to meet regulatory demands from ... Pharmacopoeia, the greatest challenge for medical device and pharmaceutical ...

Cached Medicine Technology:Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology 2 Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology 3 "Environmental Monitoring and Certification in Controlled Environments: Meeting Regulations and Achieving Effective Microbial Control for Pharmaceutical and Medical Device Manufacturers" - New White Paper from Microtest Laboratories 2

Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology "Environmental Monitoring and Certification in Controlled Environments: Meeting Regulations and Achieving Effective Microbial Control for Pharmaceutical and Medical Device Manufacturers" - New White Paper from Microtest Laboratories

(Date:6/19/2013)... CO (PRWEB) June 19, 2013 ... marketing company for coaches, announced today its affiliation ... means CoachingWebsites will offer exclusive websites and marketing ... partnerships. , “This new partnership with Active Intelligence ... their business to its fullest,” says Greer Van ...

(Date:6/19/2013)... 2013 The Mesothelioma Victims Center ... of the 2500 to 3000 citizens, who will be ... this year, about one third will be US Navy ... with this asbestos exposure form of cancer, or their ... to the nations most skilled mesothelioma compensation settlement attorneys, ...

(Date:6/19/2013)... Middle market merger and acquisition (M&A) activity ... cash rich buyers seek to place their capital in ... transactions have a good deal in common. The acquirer ... and quality of the target company’s earnings. Potential risks ... diligence involves a middle market company, whose value consists ...

(Date:6/18/2013)... 19, 2013 oBand Surgery Centers, a ... holding complimentary weight loss seminars in Los Angeles this ... be accessed at their official website. oBand Surgery Centers ... time. Their highly skilled panel of surgeons and dedicated ... , A senior executive working with oBand Surgery Centers ...

(Date:6/18/2013)... Philadelphia, PA, June 19, 2013 Recent studies ... coverage of bullying-related suicide among young people, led ... to assemble an expert panel to focus on ... about the complex relationship between youth involvement in ... Bullying among youth is a significant public health ...

Breaking Medicine News(10 mins):Health News:CoachingWebsites (Websites for Coaches) Announces Their Partnership With Active Intelligence, LLC 2 Health News:Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For Instant Access To The Nation's Top Asbestos Lawyers-Better Compensation 2 Health News:Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For Instant Access To The Nation's Top Asbestos Lawyers-Better Compensation 3 Health News:Newport Board Group, a National Business Advisory Firm of CEOs Cautions Buyers on 5 Questions to Ask Before Acquiring a Technology-Based Middle Market Company 2 Health News:Newport Board Group, a National Business Advisory Firm of CEOs Cautions Buyers on 5 Questions to Ask Before Acquiring a Technology-Based Middle Market Company 3 Health News:oBand Surgery Centers Will Hold Complimentary Weight Loss Seminars in Los Angeles in June 2 Health News:Bullying and suicide among youth is a public health problem 2

[0] CoachingWebsites (Websites for Coaches) Announces Their Partnership With Active Intelligence, LLC [0] Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For Instant Access To The Nation's Top Asbestos Lawyers-Better Compensation [0] Newport Board Group, a National Business Advisory Firm of CEOs Cautions Buyers on 5 Questions to Ask Before Acquiring a Technology-Based Middle Market Company [0] oBand Surgery Centers Will Hold Complimentary Weight Loss Seminars in Los Angeles in June [0] Bullying and suicide among youth is a public health problem

... May 11 /PRNewswire-Asia-FirstCall/ -- Mindray Medical,International Limited (NYSE: ... worldwide announced today its selected unaudited,financial results for the first ... Highlights for First Quarter 2009, -- First ... 53.5% over the first ...

... Trust Incorporated (NYSE: HR ) today announced its ... 2009. This dividend, in the amount of $0.385 per ... record on May 22, 2009. The total dividend of ... operations determined in accordance with GAAP. The Company,s cash ...

... Health Care Costs Over Next Ten Years, Provides Significant ... Year WASHINGTON, May 11 Today, key stakeholders in ... House to announce their commitment to achieving a sharp ... to prioritize preventive care, manage chronic illnesses, curtail unnecessary ...

... will be lethality of infection going forward, experts say , , ... epidemic does have pandemic potential and is likely to be ... of its spread, a new expert analysis concludes. , The ... unreported -- swine flu infections in Mexico, the outbreak,s epicenter, ...

... Call on May 14, 2009 NEW HAVEN, Conn., May 11 ... announced financial results for the first quarter of 2009. , ... $4.3 million, or $0.54 per share, for the quarter ended March ... $1.14 per share, for the same 2008 period. Weighted-average common ...

... prominently featured on the HRS 2009 programST. LOUIS, May ... said today that the Heart Rhythm 2009 formal program ... Niobe system is either featured or discussed regarding the ... efficacy data on the use of Stereotaxis, partnered magnetic ...

Mindray Announces First Quarter 2009 Financial Results Healthcare Realty Trust Announces First Quarter Dividend Kaine Lauds President Obama's Agreement With Health Care Industry Groups to Reduce Health Care Costs Study Supports Swine Flu's Pandemic Potential Vion Pharmaceuticals Reports 2009 First Quarter Results Stereotaxis' Market Leadership Highlighted at Heart Rhythm 2009

Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....

VascoStim 2F are bipolar temporary pacing leads to be used in conjunction with thermodilution catheters with implemented paceport-channel....

The Aescula LV left-heart lead is a stylet-driven, silicone insulated lead with a titanium nitride (TiN) coated platinum-iridium electrode....

Medicine Products:

VascoStim 2/5F J VascoStim 2/5F S VascoStim 2F Aescula LV Left-Heart Lead